


Highlights from the 5th Baltic PH Conference, May 9 2025

Cardiologist, prof. Andris Skride

Riga Stradins university

P.Stradins Clinical university hospital





Tallinn


- Total of 24 PAH patients
- 2 on s/c Trepostinil
- 1 inhaled Iloprost
- 2 Selexipaq

Estonia

Population: 1,326,062

Reimbursed therapies:

- **PDE-5 Inhibitors:** Sildenafil, Tadalafil
- **ERA:** Ambrisentan, Bosentan, Macitentan
- **Prostanoids:** Treprostinil, Selexipag, iloprost
- **sGC stimulator:** Riociguat

A map of Estonia with various cities labeled in Estonian and Russian. Tartu is highlighted with a large black square. Two white callout boxes provide patient data for Tartu and national reimbursement information for Estonia. The map shows the Baltic Sea to the north and the Gulf of Riga to the east.

Tartu

- Total of 22 PAH patients
- 3 triple therapy (selexipag)
- 3 triple therapy (Treprostinil)
- 2 vasoreactive on CCB
- 8 CTEPH patients on riociguat.

Estonia

Population: 1,326,062

Reimbursed therapies:

- **PDE-5 Inhibitors:** Sildenafil, Tadalafil
- **ERA:** Ambrisentan, Bosentan, Macitentan
- **Prostanoids:** Treprostinil, Selexipag, iloprost
- **sGC stimulator:** Riociguat

Lithuania

Population: 2,617,498

Reimbursed therapies:

- **PDE-5 Inhibitors:** Sildenafil, Tadalafil
- **ERA:** Ambrisentan, Bosentan, Macentan
- **Prostanoids:** Treprostinil, Selexipag, Iloprost

Vilnius

- 2022: 24 new patients with PAH (6), combined PH and CTEPH
- 8 patients with Treprostinil
- 8 patients with Selexipag

Lithuania

Population: 2,617,498

Reimbursed therapies:

- **PDE-5 Inhibitors:** Sildenafil, Tadalafil
- **ERA:** Ambrisentan, Bosentan, Macentan
- **Prostanoids:** Treprostinil, Selexipag, Iloprost

Kaunas


- Total of 125 patients (105 using medication):
- 46 - CTEPH,
- 46 - IPAH (2 hereditary),
- 17- PAH-CTD,
- 11 – PAH-CHD,
- 5- PoPAH.
- 3 patients with parenteral prostanoids: 1- i/v, 2- s/c.

LATVIA

Population: 1,828,250

Riga Pauls Stradiņš Clinical University Hospital

- 17-23 incident PAH patients each year
- Reimbursed therapies:
- **PDE-5 Inhibitors:** Sildenafil, Tadalafil
- **ERA:** Ambrisentan, Bosentan
- **Prostanoids:** Treprostinil, Selexipag, iloprost
- Riociugat – currently not reimbursed



Latvian PH centre Data

- Latvian PH registry – since **2007**
- Latvia – a part of **COMPERA** registry



OUR REGISTRY

- GROUP 1 – **161** patients
- GROUP 2 – **50** patients
- GROUP 3 – Registry started 2025Jan
- GROUP 4 – **59** patients



Latvian PH centre

Activities in novel treatments

CLINICAL TRIALS


- GROUP 1
 - Seralutinib – PDGFR inhibitor; Phase III (GOSSAMER; 12.2023. -)
 - Anti-PDGF-B monoclonal antibody; Phase II (late 2025)
 - Smad ubiquitination regulatory factor-1; PH II (NOVARTIS; 09.2025.)
 - Rho-associated coiled-coil containing protein kinase inhibitor; Phase II
- GROUP 3
 - Mosliciguat – sGC activator; Phase II (PULMOVANT; 02.2025.)
 - Inhaled Treprostinil; Phase III (LIQUIDIA; FALL 2025)
- GROUP 2 → Long-acting relaxin mimetic; Phase II (TECTONIC THERAPEUTIC; 04.2025.)

Latvian PH centre

Activities in novel treatments

BPA FOR GROUP 4

- First procedure – April, 2022;
- 33 procedures done;
- Significant hemodynamic improvement.



Baltic PH conference – what is it?

- Once every 2 years;
- First conference – Riga, Latvia, 2016;
- Presenters – leading PH specialists:
 - Baltic states;
 - Poland;
 - Others;
- Topics:
 - Recent guideline reviews;
 - Novel treatment methods;
 - Case reports;
- Audition:
 - Cardiologists, pulmonologists, family medicine physicians;
 - Medical residents;
 - Medical students;

1st Baltic Pulmonary Hypertension Conference

April 23, 2016, Radisson Blu Hotel Latvia Conference Centre, Riga, Latvia

PRELIMINARY PROGRAMME

9⁰⁰-9¹⁰ Welcome and introduction. Prof. Aivars Lejnietis, Dr. Andris Skride

Session I: PH basics and registries

9¹⁰-9⁴⁰ **PH, PAH definitions, classification, prognosis, PAH management.** Prof. Marcin Kurzyna, Poland

9⁴⁰-10⁰⁰ **The role of echocardiography in PH.** Prof. Egle Ereminiene, Lithuania

10⁰⁰-10¹⁵ **PH registry – data from Latvia.** Dr. Ainars Rudzitis, Latvia

10¹⁵-10³⁰ **PH management in Lithuania.** Dr. Lina Gumbiene, Lithuania

10³⁰-11⁴⁵ **PH registry – data from Estonia.** Prof. Alan Altraja, Estonia

10⁴⁵-11¹⁰ **Coffee break; posters**

Session II: PH diagnosis, its clinical forms

11¹⁰-11³⁰ **Radiologist's perspective in PH.** Dr. Mindaugas Mataciunas, Lithuania

11³⁰-11⁵⁰ **PH and the diseases of respiratory system.** Prof. Skaidrius Miliauskas, Lithuania

11⁵⁰-12¹⁰ **Right heart catheterization.** Dr. Ly Anton, Estonia

12¹⁰-12³⁰ **Coffee, tea break**

12³⁰-12⁵⁰ **Idiopathic PAH.** Dr. Andris Skride, Latvia

12⁵⁰-13¹⁰ **PH associated with connective tissue diseases.** Dr. Ieva Talijuniene and Dr. Rita Ruge, Lithuania

13¹⁰-13³⁰ **PAH associated with congenital heart disease.** Dr. Lina Gumbiene, Lithuania

13³⁰-14³⁰ **Lunch**

Session III: Case reports

14³⁰-15⁰⁰ **Surgery in PH: CTEPH, PEA, transplantation.** Prof. Shahrokh Taghavi, Austria

15⁰⁰-15¹⁵ **Idiopathic PAH in elderly men.** Dr. Egle Paleviciute, Lithuania

15¹⁵-15³⁰ **Case report. Choriocarcinoma mimicking CTEPH.** Kristaps Sablinskis, Latvia

15³⁰-15⁴⁵ **Case report. Patient with mixed connective tissue disease associated with PH-challenges of management.** Dr. Ly Anton, Estonia

15⁴⁵-16⁰⁰ **Case report. The importance of multimodality imaging in the patient with pulmonary hypertension.** A. Krivickiene, et al., Lithuania

16⁰⁰-16¹⁵ **Case report. 20 year old male with antiphospholipid syndrome and CTEPH.** Dr. Kaija Tammekivi, Estonia

16¹⁵-16³⁰ **Data from AMBITION Trial.** Grant Tunmer, UK


16³⁰-16⁴⁵ **Perspective & Hope: patients' point of view.** Ieva Plūme, PH Association Latvia. Chair of the Board

16⁴⁵-17⁰⁰ **Evaluation and Closing**

Riga, 1st Baltic PH conference, April 23, 2016



Arijs Skride “The Daugava river near Pļaviņas”, 1939



Vilnius, 2nd Baltic PH conference, October 19, 2018




Jonas Čeponis “Old gate”, 1988



Tallin, 3rd Baltic PH conference, October 10, 2021



Konrad Magi “Saaremaa”, 1913



Riga, 4th Baltic PH conference, April 21, 2023



Arijs Skride, «Ogre in the spring», 1964




5th Baltic PH Conference – Main Topics

- The **current situation** in PAH therapy and future treatment options;
 - By prof. Marc Humbert, leading PH researcher worldwide
- Review of **Group 1 to 4 PH** pathogenesis and newest treatment strategies;
- Focused view on **right ventricle** function and treatment;
- Challenging **cases** of PH;
- **Local research** in PH is growing – multiple excellent Abstracts from residents and students;



The current situation in PAH therapy and future treatment options

- **Triple therapy** is available worldwide;
 - ERA, PDE5-i, Prostanoids;
- **ESC guidelines on PH, 2022¹**;
 - Provide clear recommendations;
 - Maximise patients' quality of life and survival;
- **Sotatercept** – the new hope in treatment;
 - Works excellent on top of triple therapy;
 - Is still further researched for more potential benefits;
 - Not yet reimbursed in all European countries;
- **Clinical research and trials are ongoing!**
 - Targeting vascular remodeling;
 - Hope for further addition to pharmacotherapy;
 - Personalized medicine?




<https://www.nejm.org/doi/full/10.1056/NEJMoa2024277>

Future perspectives in treatment of Group 2 PH



CLINICAL STUDY PROTOCOL

- Potential drug for Group 2 PH
- A phase II Randomized Controlled Study
- TX000045 - human **relaxin-2**-Fc fusion protein
- 1st patient for Latvian PH centre screened on April 16, 2025
- 3 patients screened;
2 – randomized;



Title	A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Study Number	TX000045-003
Study Intervention	TX000045
Brief Title	A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) (the APEX Study)
EU CT Number	2024-514283-40-00
Study Phase	2
Sponsor	Tectonic Therapeutic 490 Arsenal Way, Suite 210 Watertown, MA 02472 USA
Sponsor Medical Monitor	Marcella Ruddy, MD 490 Arsenal Way, Suite 210 Watertown, MA 02472 USA Phone: +1 339 526-2849
Original Protocol (Version 1.0)	03 May 2024
Global Protocol Amendment 1.0	22 May 2024
Global Protocol Amendment 2.0	21 June 2024


Group 1 to 4 PH pathogenesis and newest treatment strategies

Group 3

- **Classification** for Group 3¹:
 - **Mild PH**: mPAP > 20 mmHg; PCWP ≤ 15 mmHg; **PVR < 2 WU**
 - **Severe PH**: mPAP > 35 mmHg OR RAP > 15 mmHg OR CI < 2.5 L/min/m²
- In severe PH – **pulmonary vascular phenotype** is changed
- Clinically may **overlap** with Group 1
 - DLCO < 45%
 - PVR ≥ 5 WU
 - HRCT – less fibrosis than expected




- **PAH therapy** might be beneficial
- **Treat the underlying lung disease!**
- **Clinical trials** are ongoing!



<https://www.mdpi.com/1422-0067/26/2/835>

Local research in PH in Baltics



- 12 Abstract presenters from Lithuania, Latvia, Sweden
- Doctors, residents, students
- **Epidemiological** research
 - Mortality associated with medication availability;
 - Patient quality of life;
- Implementation of **innovative methods**
 - Percutaneous mechanical thrombectomy for PE;
- **Preclinical** research
 - Morphology of pulmonary arteries;
- **Cohort** studies
 - PH-ILD IPF subgroup analysis;
 - PH-ILD instrumental examination correlations;
 - SPESI score and PH probability correlation;



Local research in PH in Baltics

The winner of abstract session

A dissected model of pulmonary arteries



- Used in invasive pulmonary angiography and BPA;
- Improved recognition of pulmonary segmental arteries


Local research in PH in Baltics

The winner of abstract session

A dissected model of pulmonary arteries

Segmental arteries of the pulmonary arterial tree

- 1 – A1/Apical
- 2 – A2/Posterior
- 3 – A3/Anterior
- 4 – A4/Lateral
- 5 – A5/Medial
- 6 – A6/Superior
- 7 – A7/Medial basal
- 8 – A8/Anterior basal
- 9 – A9/Lateral basal
- 10 – A10/Posterior basal



Right lung

Left lung

- 1 – A1/Apical
- 2 – A2/Posterior
- 3 – A3/Anterior
- 4 – A4/Lateral
- 5 – A5/Medial
- 6 – A6/Superior
- (7 – A7/Medial basal)
- 8 – A8/Anterior basal
- 9 – A9/Lateral basal
- 10 – A10/Posterior basal


Local research in PH in Baltics

The winner of abstract session

A dissected model of pulmonary arteries

Statistical analysis of arteries' generations and mean lengths			
Generation	Mean, mm	SD, mm	CV, %
2	31.31	1.85	5.89
3	17.83	5.79	32.47
4	24.86	13.44	54.06
5	21.46	9.82	45.69

Statistical analysis of arteries' generations and mean diameters			
Generation	Mean, mm	SD, mm	CV, %
2	25.91	0.04	0.15
3	6.58	1.73	26.29
4	5.59	0.90	16.03
5	4.89	1.41	28.88



Thank You!

30.06.2025.

DRS
R